KalVista Pharmaceuticals (KALV) Stock Forecast & Price Target

Compare

459 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KALV Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

KalVista

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KALV Stock 12 Month Forecast

Average Price Target

$28.00

▲(143.48%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for KalVista Pharmaceuticals in the last 3 months. The average price target is $28.00 with a high forecast of $39.00 and a low forecast of $19.00. The average price target represents a 143.48% change from the last price of $11.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","40":"$40","15.25":"$15.25","23.5":"$23.5","31.75":"$31.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,15.25,23.5,31.75,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.92,14.926153846153845,16.932307692307692,18.93846153846154,20.944615384615382,22.950769230769232,24.956923076923076,26.96307692307692,28.96923076923077,30.975384615384613,32.98153846153846,34.987692307692306,36.99384615384615,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.92,14.08,15.24,16.4,17.56,18.72,19.88,21.04,22.2,23.36,24.52,25.68,26.839999999999996,{"y":28,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.92,13.387692307692308,13.855384615384615,14.323076923076924,14.79076923076923,15.258461538461539,15.726153846153846,16.193846153846152,16.661538461538463,17.12923076923077,17.596923076923076,18.064615384615387,18.532307692307693,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.4,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.18,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.67,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.89,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.39,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$39.00

Average Price Target$28.00

Lowest Price Target$19.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/24/25

Optimistic Buy Rating for KalVista Pharmaceuticals Amidst Positive FDA Interactions and Imminent Decision on Sebetralstat

Debanjana ChatterjeeJonesTrading

JonesTrading

$30

Buy

160.87%

Upside

Reiterated

06/24/25

KalVista selloff on Endpoints report unwarranted, says JonesResearchKalVista selloff on Endpoints report unwarranted, says JonesResearch

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$20→$39

Buy

239.13%

Upside

Assigned

06/24/25

Stifel calls report of Makary pushing for KalVista CRL 'highly surprising'Stifel calls report of Makary pushing for KalVista CRL 'highly surprising'

Jonathan WollebenCitizens JMP

Citizens JMP

$19

Buy

65.22%

Upside

Reiterated

06/16/25

Citizens JMP Keeps Their Buy Rating on KalVista Pharmaceuticals (KALV)

Serge BelangerNeedham

Needham

$28

Buy

143.48%

Upside

Reiterated

06/16/25

Optimistic Buy Rating for KalVista Pharmaceuticals Amid FDA Delay

Stacy KuTD Cowen

TD Cowen

$30

Buy

160.87%

Upside

Reiterated

06/16/25

Analysts Offer Insights on Healthcare Companies: Immuneering (NASDAQ: IMRX) and KalVista Pharmaceuticals (NASDAQ: KALV)

Tazeen AhmadBank of America Securities

Bank of America Securities

$22

Buy

91.30%

Upside

Reiterated

06/13/25

KalVista Pharmaceuticals: Buy Rating on Promising Oral HAE Treatment and Market Readiness

Charles DuncanCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

03/26/25

Cantor Fitzgerald reiterates Overweight Rating on Kalvista Pharmaceuticals Inc (KALV)Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).

Maury RaycroftJefferies

Jefferies

$31

Buy

169.57%

Upside

Assigned

03/26/25

Analysts Are Bullish on These Healthcare Stocks: Phreesia (PHR), Acrivon Therapeutics, Inc. (ACRV)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$20

Buy

73.91%

Upside

Reiterated

03/14/25

Promising Potential of Sebetralstat: A Game-Changer in Hereditary Angioedema Treatment

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/24/25

Optimistic Buy Rating for KalVista Pharmaceuticals Amidst Positive FDA Interactions and Imminent Decision on Sebetralstat

Debanjana ChatterjeeJonesTrading

JonesTrading

$30

Buy

160.87%

Upside

Reiterated

06/24/25

KalVista selloff on Endpoints report unwarranted, says JonesResearchKalVista selloff on Endpoints report unwarranted, says JonesResearch

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$20→$39

Buy

239.13%

Upside

Assigned

06/24/25

Stifel calls report of Makary pushing for KalVista CRL 'highly surprising'Stifel calls report of Makary pushing for KalVista CRL 'highly surprising'

Jonathan WollebenCitizens JMP

Citizens JMP

$19

Buy

65.22%

Upside

Reiterated

06/16/25

Citizens JMP Keeps Their Buy Rating on KalVista Pharmaceuticals (KALV)

Serge BelangerNeedham

Needham

$28

Buy

143.48%

Upside

Reiterated

06/16/25

Optimistic Buy Rating for KalVista Pharmaceuticals Amid FDA Delay

Stacy KuTD Cowen

TD Cowen

$30

Buy

160.87%

Upside

Reiterated

06/16/25

Analysts Offer Insights on Healthcare Companies: Immuneering (NASDAQ: IMRX) and KalVista Pharmaceuticals (NASDAQ: KALV)

Tazeen AhmadBank of America Securities

Bank of America Securities

$22

Buy

91.30%

Upside

Reiterated

06/13/25

KalVista Pharmaceuticals: Buy Rating on Promising Oral HAE Treatment and Market Readiness

Charles DuncanCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

03/26/25

Maury RaycroftJefferies

Jefferies

$31

Buy

169.57%

Upside

Assigned

03/26/25

Analysts Are Bullish on These Healthcare Stocks: Phreesia (PHR), Acrivon Therapeutics, Inc. (ACRV)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$20

Buy

73.91%

Upside

Reiterated

03/14/25

Promising Potential of Sebetralstat: A Game-Changer in Hereditary Angioedema Treatment

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering KalVista Pharmaceuticals

1 Month

xxx

Success Rate

10/22 ratings generated profit

Average Return

-0.35%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 45.45% of your transactions generating a profit, with an average return of -0.35% per trade.

3 Months

xxx

Success Rate

12/22 ratings generated profit

Average Return

+7.52%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +7.52% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

15/22 ratings generated profit

Average Return

+17.59%

reiterated a buy rating 4 days ago

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +17.59% per trade.

2 Years

xxx

Success Rate

14/22 ratings generated profit

Average Return

+18.45%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +18.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KALV Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KALV has received 35 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KALV average Analyst price target in the past 3 months is 28.00.

Each month's total comprises the sum of three months' worth of ratings.

KALV Financial Forecast

KALV Earnings Forecast

Next quarter’s earnings estimate for KALV is -$0.84 with a range of -$0.95 to -$0.73. The previous quarter’s EPS was -$0.92. KALV beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.18% of the time in the same period. In the last calendar year KALV has Outperformed its overall industry.

KALV Sales Forecast

Next quarter’s sales forecast for KALV is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KALV beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 38.35% of the time in the same period. In the last calendar year KALV has Preformed in-line its overall industry.

KALV Stock Forecast FAQ

What is KALV’s average 12-month price target, according to analysts?

Based on analyst ratings, KalVista Pharmaceuticals’s 12-month average price target is 28.00.

What is KALV’s upside potential, based on the analysts’ average price target?

KalVista Pharmaceuticals has 143.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KALV a Buy, Sell or Hold?

KalVista Pharmaceuticals has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is KalVista Pharmaceuticals’s price target?

The average price target for KalVista Pharmaceuticals is 28.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $39.00 ,the lowest forecast is $19.00. The average price target represents 143.48% Increase from the current price of $11.5.

What do analysts say about KalVista Pharmaceuticals?

KalVista Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of KALV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

KalVista Pharmaceuticals (KALV) Stock Forecast & Price Target

KALV Analyst Ratings

KALV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering KalVista Pharmaceuticals

KALV Analyst Recommendation Trends

KALV Financial Forecast

KALV Earnings Forecast

KALV Sales Forecast

KALV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts